论文部分内容阅读
目的观察布地奈德吸入疗法、孟鲁司特钠咀嚼片及抗过敏药对婴幼儿肺炎支原体(MP)感染致慢性咳嗽的疗效。方法选取180例MP感染致慢性咳嗽的婴幼儿,在用抗生素治疗的基础上,随机分成4组:原方案组、布地奈德组、孟鲁司特组及氯雷他定组。用药前后检测外周静脉血嗜酸粒细胞阳离子蛋白(ECP)、嗜酸粒细胞(EOS)、IL-4和总IgE(T-IgE)水平。结果布地奈德组、孟鲁司特组和氯雷他定组临床症状消失时间较原方案组均显著缩短(Pa<0.01);且3个月内反复呼吸道感染次数亦显著减少(Pa<0.01);布地奈德组疗程最短。原方案组除ECP在用药后降低外,EOS、IL-4和T-IgE均无明显变化;而布地奈德组、孟鲁司特组和氯雷他定组用药后ECP、EOS和IL-4均明显下降,差异有统计学意义(Pa<0.01),T-IgE水平无明显变化。结论小剂量布地奈德吸入可缩短慢性咳嗽疗程,孟鲁司特钠咀嚼片及抗过敏药能促进咳嗽康复,降低复发频率。
Objective To observe the curative effect of budesonide inhalation therapy, montelukast sodium chewable tablets and anti-allergy drugs on chronic cough caused by Mycoplasma pneumoniae (MP) infection in infants and young children. Methods 180 infants and children with chronic cough caused by MP infection were selected and randomly divided into 4 groups according to the antibiotic treatment: the original plan group, budesonide group, montelukast group and loratadine group. Peripheral venous blood eosinophil cationic protein (ECP), eosinophils (EOS), IL-4 and total IgE (T-IgE) levels were measured before and after treatment. Results The disappearance time of clinical symptoms in the budesonide group, the montelukast group and the loratadine group was significantly shorter than those in the original regimen group (Pa0.01), and the number of recurrent respiratory tract infections was also significantly decreased in 3 months (Pa0.01 ); Budesonide group the shortest course of treatment. ECP, IL-4 and T-IgE had no significant changes in ECP, EOS and IL-4 in budesonide, montelukast and loratadine groups, 4 were significantly decreased, the difference was statistically significant (Pa <0.01), T-IgE levels did not change significantly. Conclusion Small doses of budesonide inhalation can shorten the course of chronic cough, montelukast sodium chewable tablets and anti-allergic drugs can promote cough healing, reduce the frequency of relapse.